Beam Therapeutics Inc , a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States.
infoBeam Therapeutics is a small cap stock with a total market cap of 1.86B.
infoThey trade on the NASDAQ and had their IPO 3 years and 6 months ago.
infoBeam Therapeutics currently employs 532 people.
infoAs of Wednesday, Aug 23 2023, Beam Therapeutics’s share price is $23.5.
News Relating to Beam Therapeutics
The Motley Fool
Got $200? 3 Growth Stocks to Buy That Could Double Your Money
Saturday Aug 19 2023 at 05:52
Axsome Therapeutics has two approved products and a promising pipeline. Beam Therapeutics’ base-editing technology could be a huge moneymaker over time.
Zacks Investment Research
Down -20.85% in 4 Weeks, Here’s Why Beam Therapeutics Inc. (BEAM) Looks Ripe for a Turnaround
Friday Aug 11 2023 at 10:47
Beam Therapeutics Inc. (BEAM) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Zacks Investment Research
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
Tuesday Aug 08 2023 at 09:10
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.38. This compares to loss of $1.02 per share a year ago.
The Motley Fool
2 Supercharged Growth Stocks That Could Make You Richer
Saturday Jul 15 2023 at 15:45
Innovation-oriented growth companies, while risky, can deliver life-altering returns on capital for patient investors. Beam Therapeutics and Nano-X Imaging are angling to upend the status quo for multiple healthcare markets.
Seeking Alpha
Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year
Saturday May 20 2023 at 08:00
Beam is a leader in base editing and has strong lab data. It has a huge amount of cash and a major deal with Pfizer.
GlobeNewsWire
Beam Therapeutics to Participate in Upcoming May Investor Conferences
Wednesday May 17 2023 at 06:30
CAMBRIDGE, Mass., May 17, 2023 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management plans to participate in fireside chats during the following May investor conferences:
The Motley Fool
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
Tuesday May 16 2023 at 05:50
Cathie Wood’s Ark Invest ETFs added to their positions recently in two biotech stocks and one telehealth stock. All three stocks have plunged over the past couple of years.
GlobeNewsWire
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
Thursday May 11 2023 at 06:30
CAMBRIDGE, Mass., May 11, 2023 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, plans to participate in a fireside chat during the RBC Capital Markets 2023 Global Healthcare Conference on Wednesday, May 17, 2023, at 11:00 a.m. ET in NYC.
Zacks Investment Research
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates
Wednesday May 10 2023 at 09:09
Beam Therapeutics Inc. (BEAM) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.36. This compares to loss of $1.01 per share a year ago.
InvestorPlace
7 Best Cathie Wood Stocks for Your May 2023 Buy List
Tuesday May 02 2023 at 12:25
Cathie Wood invests in speculative stocks that don’t always pan out, as 2022 showed. The chief of Ark Investment Management watched her firm outperform in 2021, though last year saw a sharp deceleration in interest in various hough-growth names.
The Motley Fool
3 Growth Stocks Cathie Wood Just Bought That Could Be Absolute Game-Changers
Tuesday May 02 2023 at 05:53
Beam Therapeutics is a pioneer in base editing, an especially promising type of gene editing. CRISPR Therapeutics could soon bring the first CRISPR gene-editing therapy to market.
InvestorPlace
The 3 Most Promising Gene Editing Stocks to Buy in 2023
Friday Apr 28 2023 at 16:51
Gene editing stocks are one of the hottest sectors in medicine today. Genes are the foundation of life, and from creating new organisms to curing incurable diseases, the editing of genes can bring radical changes to life as we know it.
InvestorPlace
3 Stocks to Watch in April: Is it Time to Buy?
Tuesday Apr 18 2023 at 15:47
Heading toward the midway point of the year, the unique dynamics associated with the post-pandemic new normal sets the stage for certain stocks to watch. That is, brewing fundamental and technical factors appear to favor fortuitously structured or positioned enterprises.
InvestorPlace
7 Top Growth Stocks to Buy for the Next Decade
Tuesday Apr 18 2023 at 07:00
A the market returns it’s time to look for the best growth stocks to buy. successful investing strategy partially requires an ability to predict the future.
Benzinga
Cathie Wood Loads Up On Biotech Stocks — Continues To Raise Stake In Coinbase Global
Thursday Apr 06 2023 at 00:15
Cathie Wood-led ARK Investment Management raised stakes in a number of biotech companies on Wednesday with these stocks recording negative returns over the last one month, potentially making them attractive in terms of valuations.
InvestorPlace
7 Biotech Stocks to Buy for Breakthrough Treatments and Cures
Wednesday Mar 29 2023 at 20:54
While it’s a common conspiracy theory – and comedic punchline – that medical innovators only seek to manage problems rather than cure them, the reality is that several biotech stocks to buy undergird myriad therapeutic advancements. For patients, they represent hope for a positive outcome.
GlobeNewsWire
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
Wednesday Mar 15 2023 at 06:30
CAMBRIDGE, Mass., March 15, 2023 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Giuseppe Ciaramella, Ph.D., president of Beam, will participate in a fireside chat during the Barclays 2023 Global Healthcare Conference on Thursday, March 16, 2023 at 8:30 a.m. ET in Miami, FL.
InvestorPlace
3 CRISPR Gene Editing Stocks to Consider for Ground-Floor Investing
Monday Mar 06 2023 at 12:13
The 2022 Nobel Prize in Chemistry went to Emmanuelle Charpentier and Jennifer Doudna for their work on developing tools to change the genetic code of living cells, tools called CRISPR/Cas. Yet long before their trip to Stockholm, they and other scientists had been diligently founding companies to monetize this new discovery.
InvestorPlace
The Top 7 Growth Stocks in Biotech
Friday Mar 03 2023 at 18:57
Biotech stocks almost always have the potential for significant growth over time. Companies in the sector operate in areas including drug development, medical devices, and diagnostics.
Zacks Investment Research
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
Tuesday Feb 28 2023 at 09:02
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 59.09% and 69.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
Beam Therapeutics: An Upgraded View
Thursday Feb 23 2023 at 15:18
Today, we are putting Beam Therapeutics back in the spotlight after an initial article on this gene editing name last summer. Beam Therapeutics’ stock has sunk by a third since that avoid recommendation, but the shares have recently been upgraded by several analyst firms.
The Motley Fool
Better Buy: Beam Therapeutics or Intellia Therapeutics?
Wednesday Feb 22 2023 at 06:00
The two clinical-stage gene-editing companies have good long-term prospects.
InvestorPlace
7 CRISPR Stocks With the Best Long-Term Potential
Monday Jan 30 2023 at 19:10
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.
The Motley Fool
5 Top Stocks for February
Sunday Jan 29 2023 at 05:45
These growth stocks have more room to run.
The Motley Fool
3 Great Growth Stocks Down 20% or More to Buy Now
Friday Jan 27 2023 at 09:37
These beaten-down stocks could be poised for major rebounds.
The Motley Fool
3 Stocks That Could Create Lasting Generational Wealth
Sunday Jan 15 2023 at 05:50
Making money that spans generations requires thinking big.
Seeking Alpha
10 Potential 10x Return Stocks For The Next 10 Years
Wednesday Jan 04 2023 at 11:04
While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.
GlobeNewsWire
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Tuesday Jan 03 2023 at 06:30
CAMBRIDGE, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, Jan. 9, 2023 at 11:15 a.m. PT in San Francisco.
The Motley Fool
3 Under-the-Radar Biotech Stocks to Buy in 2022
Saturday Dec 24 2022 at 10:07
The attraction of all three biotech stocks is their potential.
InvestorPlace
7 ‘Next Big Things’ for Investors to Buy for 2023
Tuesday Dec 13 2022 at 13:16
The next big things for investors are always around the corner. As investors say goodbye to the 2022 bear market, we look forward to what could be an excellent 2023.
Beam Therapeutics Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
Beam Therapeutics’s Altman Z-score is 0.7 which is in the distress zone. This indicates a higher risk of financial distress and potential bankruptcy for the company. It can serve as a warning sign of significant financial challenges, requiring careful consideration by potential investors.
Derived from SEC.GOV filing dataopen_in_new
Beam Therapeutics Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $11.92K of common stock in Beam Therapeutics on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
Beam Therapeutics’s Income Quality of 0.76 is greater than its Industry Group of 0.69 (10.1% greater)
Beam Therapeutics’s Income Quality of 0.76 is in line with its Major Industry Group of 0.71 (7.0% greater)
Beam Therapeutics’s Income Quality of 0.76 is in line with its Sector of 0.75 (1.3% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
Beam Therapeutics’s Current Ratio of 5.22 is in line with its Industry Group of 4.76 (9.7% greater)
Beam Therapeutics’s Current Ratio of 5.22 is greater than its Major Industry Group of 4.32 (20.8% greater)
Beam Therapeutics’s Current Ratio of 5.22 is greater than its Sector of 2.6 (100.8% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-5.91 & -1.27)
Cannot compare a negative PE Ratio (-5.91 & -1.1)
Cannot compare a negative PE Ratio (-5.91 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
Beam Therapeutics’s PB Ratio of 2.29 is greater than its Industry Group of 1.34 (70.9% greater)
Beam Therapeutics’s PB Ratio of 2.29 is greater than its Major Industry Group of 1.4 (63.6% greater)
Beam Therapeutics’s PB Ratio of 2.29 is greater than its Sector of 1.62 (41.4% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
Beam Therapeutics’s ROE of -0.39 is greater than its Industry Group of -0.44 (11.4% greater)
Beam Therapeutics’s ROE of -0.39 is in line with its Major Industry Group of -0.38 (-2.6% lower)
Beam Therapeutics’s ROE of -0.39 is lower than its Sector of -0.03 (-1200.0% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
Beam Therapeutics’s ROCE of -0.33 is greater than its Industry Group of -0.42 (21.4% greater)
Beam Therapeutics’s ROCE of -0.33 is greater than its Major Industry Group of -0.37 (10.8% greater)
Beam Therapeutics’s ROCE of -0.33 is lower than its Sector of -0.04 (-725.0% lower)
Derived from SEC.GOV filing dataopen_in_new